AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17179265 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 30
Study 15130166 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel VAS device
Number of subjects: 134
Study 15130166 — intervention group
Group type: COMPARATOR
Intervention: Paper VAS
Number of subjects: 134
Study 11548874 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4mg/day for 4 weeks)
Number of subjects: 21
Study 11548874 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day for 4 weeks)
Number of subjects: 21
Study 11548874 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (5 mg/day for 4 weeks)
Number of subjects: 21
Study 9718471 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 150 mg single dose
Number of subjects: 40
Study 9718471 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole 100 mg for 7 days
Number of subjects: 40
Study 7925264 — intervention group
Group type: EXPERIMENTAL
Intervention: VDT work (text-editing) for 3 hours
Number of subjects: 51
Study 7925264 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical corrections
Number of subjects: 51
Study 7925264 — intervention group
Group type: COMPARATOR
Intervention: Distance viewing (control group) for 3 hours
Number of subjects: 51
Study 2813011 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting conditions during Ramadan (Experiment 1)
Number of subjects: 70
Study 2813011 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting conditions (Experiment 2)
Number of subjects: 70
Study 2813011 — intervention group
Group type: COMPARATOR
Intervention: Nonfasting conditions (Experiment 1)
Number of subjects: 70
Study 2813011 — intervention group
Group type: COMPARATOR
Intervention: Nonfasting conditions (Experiment 2)
Number of subjects: 70
Study 1234410 — intervention group
Group type: EXPERIMENTAL
Intervention: Synovectomy of the knee
Number of subjects: 0
Study 1234410 — intervention group
Group type: COMPARATOR
Intervention: Observation without operation (Control)
Number of subjects: 0
Study 30929250 — intervention group
Group type: EXPERIMENTAL
Intervention: LAA amputation
Number of subjects: 21
Study 30929250 — intervention group
Group type: COMPARATOR
Intervention: No LAA amputation
Number of subjects: 21
Study 30929250 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study 30457018 — intervention group
Group type: EXPERIMENTAL
Intervention: Itopride HCl 150 mg ER pellets
Number of subjects: 12
Study 30457018 — intervention group
Group type: COMPARATOR
Intervention: Ganaton ER 150 mg OD tablets
Number of subjects: 12
Study 29231340 — intervention group
Group type: EXPERIMENTAL
Intervention: Herb-partitioned moxibustion on navel
Number of subjects: 40
Study 29231340 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene
Number of subjects: 40
Study 25567821 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching by medical assistants
Number of subjects: 0
Study 25567821 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 24168427 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture intervention measures
Number of subjects: 0
Study 24168427 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (pseudotarget disease)
Number of subjects: 0
Study 21797975 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 162
Study 21797975 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A (CsA)
Number of subjects: 162
Study 19553269 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound screening invitation (invited group)
Number of subjects: 67770
Study 19553269 — intervention group
Group type: COMPARATOR
Intervention: Control group not offered screening
Number of subjects: 67770
Study 16772388 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity inspiratory muscle training (H-IMT)
Number of subjects: 33
Study 16772388 — intervention group
Group type: COMPARATOR
Intervention: Sham inspiratory muscle training (S-IMT)
Number of subjects: 33
Study 15273637 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 72
Study 15273637 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 72
Study 11523071 — intervention group
Group type: EXPERIMENTAL
Intervention: Test treatment (three doses)
Number of subjects: 0
Study 9029644 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of rotavirus groups A, B, and C using polymerase chain reaction/enzyme immunoassay in biliary atresia patients.
Number of subjects: 24
Study 9029644 — intervention group
Group type: COMPARATOR
Intervention: Detection of rotavirus groups A, B, and C using polymerase chain reaction/enzyme immunoassay in control patients.
Number of subjects: 24
Study 8380631 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C, vinblastine and cisplatin (MVP)
Number of subjects: 28
Study 8380631 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus etoposide
Number of subjects: 28
Study 6354153 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleic acid treatment
Number of subjects: 0
Study 6354153 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30896650 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 62
Study 30896650 — intervention group
Group type: COMPARATOR
Intervention: No specific intervention mentioned
Number of subjects: 62
Study 28721837 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training combined with a protein-enriched lean red meat diet (RT+Meat)
Number of subjects: 100
Study 28721837 — intervention group
Group type: COMPARATOR
Intervention: Control group (CRT) - ≥1 serving/d (25-30 g) carbohydrates
Number of subjects: 100
Study 25992660 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam Roll (FOAM)
Number of subjects: 40
Study 25992660 — intervention group
Group type: EXPERIMENTAL
Intervention: Contract-relax PNF stretching (CRPNF)
Number of subjects: 40
Study 25992660 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 40
Study 25084499 — intervention group
Group type: EXPERIMENTAL
Intervention: Stigma reduction intervention (video watched weekly for 4 weeks)
Number of subjects: 99
Study 25084499 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 99
Study 22562296 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketorolac tromethamine 0.4% eyedrops
Number of subjects: 40
Study 22562296 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic artificial tears
Number of subjects: 40
Study 22562296 — intervention group
Group type: COMPARATOR
Intervention: No drops (control)
Number of subjects: 40
Study 18836741 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual and auditory features combined in Experiment 1
Number of subjects: 0
Study 18836741 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory and tactile features combined in Experiment 2
Number of subjects: 0
Study 17313291 — intervention group
Group type: EXPERIMENTAL
Intervention: 3L-1UB (trained 3 sets in leg exercises and 1 set in upper-body exercises; n = 11)
Number of subjects: 21
Study 17313291 — intervention group
Group type: COMPARATOR
Intervention: 1L-3UB (trained 1 set in leg exercises and 3 sets in upper-body exercises; n = 10)
Number of subjects: 21
Study 17313291 — intervention group
Group type: EXPERIMENTAL
Intervention: 3L-1UB
Number of subjects: 21
Study 17313291 — intervention group
Group type: COMPARATOR
Intervention: 1L-3UB
Number of subjects: 21
Study 16986068 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose of proton pump inhibitor (PPI) until symptoms resolve for NERD or until complete remission for erosive disease.
Number of subjects: 0
Study 16986068 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose PPI for maintenance treatment.
Number of subjects: 0
Study 16986068 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand therapy with half-dose PPI for NERD patients in remission.
Number of subjects: 0
Study 16986068 — intervention group
Group type: EXPERIMENTAL
Intervention: Return to full-dose PPI for relapse of symptoms.
Number of subjects: 0
Study 16986068 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term treatment with PPIs.
Number of subjects: 0
Study 12773078 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent chromium supplementation
Number of subjects: 0
Study 10547214 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 70
Study 10547214 — intervention group
Group type: COMPARATOR
Intervention: Soluble human insulin
Number of subjects: 70
Study 8735555 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-RG (10^4.5 TCID50)
Number of subjects: 0
Study 8735555 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-RG (10^5.5 TCID50)
Number of subjects: 0
Study 8735555 — intervention group
Group type: COMPARATOR
Intervention: HDCV (standard human diploid cell rabies vaccine)
Number of subjects: 0
Study 8735555 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-RG (lowest dose 10^3.5 TCID50)
Number of subjects: 0
Study 8735555 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-RG (booster dose at day 180)
Number of subjects: 0
Study 1836227 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced warm air
Number of subjects: 90
Study 1836227 — intervention group
Group type: COMPARATOR
Intervention: Warmed cotton blankets
Number of subjects: 90
Study 1836227 — intervention group
Group type: COMPARATOR
Intervention: Radiant heat lamps
Number of subjects: 90
Study 6358282 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate
Number of subjects: 40
Study 6358282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31853633 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based CBT-I
Number of subjects: 83
Study 31853633 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help CBT-I
Number of subjects: 83
Study 31853633 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene control
Number of subjects: 83
Study 31233507 — intervention group
Group type: EXPERIMENTAL
Intervention: IDA (ivermectin 200 μg/kg, diethylcarbamazine 6 mg/kg, albendazole 400 mg)
Number of subjects: 26836
Study 31233507 — intervention group
Group type: COMPARATOR
Intervention: DA (diethylcarbamazine plus albendazole)
Number of subjects: 26836
Study 28128223 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous saline post procedure (Group A)
Number of subjects: 617
Study 28128223 — intervention group
Group type: COMPARATOR
Intervention: No intravenous fluids post-procedure (Group B)
Number of subjects: 617
Study 28128223 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 617
Study 26200619 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement of malnutrition (IOM)
Number of subjects: 108
Study 26200619 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of inflammation (ROI)
Number of subjects: 108
Study 26200619 — intervention group
Group type: COMPARATOR
Intervention: Both IOM and ROI groups
Number of subjects: 108
Study 23531998 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant (AO) supplementation for 3 months
Number of subjects: 61
Study 23531998 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) for 3 months
Number of subjects: 61
Study 21755823 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunocapture test
Number of subjects: 211
Study 21755823 — intervention group
Group type: COMPARATOR
Intervention: Coombs test
Number of subjects: 211
Study 21755823 — intervention group
Group type: COMPARATOR
Intervention: SAT
Number of subjects: 211
Study 21755823 — intervention group
Group type: COMPARATOR
Intervention: 2-ME test
Number of subjects: 211
Study 19426126 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab given intravenously once a month
Number of subjects: 0
Study 17173514 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (750 mg PO daily)
Number of subjects: 16
Study 17173514 — intervention group
Group type: COMPARATOR
Intervention: Control (no acetazolamide)
Number of subjects: 16
Study 17173514 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (with and without Actz)
Number of subjects: 16
Study 14505753 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of mifepristone administered on day LH+2
Number of subjects: 14
Study 10833761 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal-frame backpack
Number of subjects: 20
Study 10833761 — intervention group
Group type: COMPARATOR
Intervention: External-frame backpack
Number of subjects: 20
Study 9166270 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoluminal repair
Number of subjects: 117
Study 9166270 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 117
Study 1533941 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded activity program
Number of subjects: 103
Study 1533941 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study 2908814 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam 50 mg
Number of subjects: 2
Study 2908814 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam 100 mg
Number of subjects: 2
Study 2908814 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam 150 mg
Number of subjects: 2
Study 2908814 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg + Fenoldopam 100 mg
Number of subjects: 2
Study 2908814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 2908814 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 20 mg + Placebo
Number of subjects: 2
Study 30695836 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire group (QG) - received questionnaires assessing well-being, completed three times on the day of donation and four times over 8 weeks with reminder calls.
Number of subjects: 217
Study 30695836 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - not contacted with a questionnaire.
Number of subjects: 217
Study 30695836 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire group (QG) - received questionnaires assessing well-being.
Number of subjects: 217
Study 30486849 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS with a small active cathode (4 × 4 cm2)
Number of subjects: 18
Study 30486849 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS with a large, functionally inert cathode (10 × 10 cm2)
Number of subjects: 18
Study 30486849 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 18
Study 30486849 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (all montages)
Number of subjects: 18
Study 27271183 — intervention group
Group type: EXPERIMENTAL
Intervention: Volanesorsen 300 mg
Number of subjects: 15
Study 27271183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 25415818 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.2 microgram/kg
Number of subjects: 50
Study 25415818 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 50
Study 22464212 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic follow-up at 8 months ± 28 days
Number of subjects: 1002
Study 22464212 — intervention group
Group type: COMPARATOR
Intervention: Clinical follow-up alone
Number of subjects: 1002
Study 22464212 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic follow-up with paclitaxel-eluting stent (PES)
Number of subjects: 1002
Study 22464212 — intervention group
Group type: COMPARATOR
Intervention: Clinical follow-up with paclitaxel-eluting stent (PES)
Number of subjects: 1002
Study 22464212 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic follow-up with everolimus-eluting stent
Number of subjects: 1002
Study 22464212 — intervention group
Group type: COMPARATOR
Intervention: Clinical follow-up with everolimus-eluting stent
Number of subjects: 1002
Study 20019137 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Body Weight (TBW) group (0.6 g of iodine per kilogram of TBW)
Number of subjects: 120
Study 20019137 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean Body Weight (LBW) group (0.821 g of iodine per kilogram of LBW)
Number of subjects: 120
Study 20019137 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Volume (BV) group (men, 8.6 g of iodine per liter of BV; women, 9.9 g of iodine per liter of BV)
Number of subjects: 120
Study 20019137 — intervention group
Group type: COMPARATOR
Intervention: Lean Body Weight (LBW) group
Number of subjects: 120
Study 20019137 — intervention group
Group type: COMPARATOR
Intervention: Total Body Weight (TBW) group
Number of subjects: 120
Study 20019137 — intervention group
Group type: COMPARATOR
Intervention: Blood Volume (BV) group
Number of subjects: 120
Study 18024370 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with idarubicin and cytarabine plus lomustine (ICL)
Number of subjects: 364
Study 18024370 — intervention group
Group type: COMPARATOR
Intervention: Induction therapy with idarubicin and cytarabine (IC)
Number of subjects: 364
Study 16118354 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative morphine (10 mg IV) and postoperative OMT
Number of subjects: 39
Study 16118354 — intervention group
Group type: COMPARATOR
Intervention: Preoperative saline (control) and postoperative OMT
Number of subjects: 39
Study 16118354 — intervention group
Group type: COMPARATOR
Intervention: Preoperative saline (control) and postoperative sham manipulative treatment
Number of subjects: 39
Study 16118354 — intervention group
Group type: COMPARATOR
Intervention: Preoperative morphine (10 mg IV) and postoperative sham manipulative treatment
Number of subjects: 39
Study 11383326 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/d atorvastatin for 10 or more weeks
Number of subjects: 42
Study 11383326 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.68 g/d omega-3 FA (ethylesters of eicosapentaenoic and docosahexaenoic acids)
Number of subjects: 42
Study 11383326 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 42
Study 9734349 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids
Number of subjects: 2145
Study 9734349 — intervention group
Group type: COMPARATOR
Intervention: Steroid nonusers
Number of subjects: 2145
Study 8067227 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 40
Study 8067227 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 40
Study 8067227 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Isoflurane and Nitroglycerin)
Number of subjects: 40
Study 3057655 — intervention group
Group type: COMPARATOR
Intervention: Marevan (Allen & Hanburys)
Number of subjects: 12
Study 3057655 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (Petersen)
Number of subjects: 12
Study 3057655 — intervention group
Group type: EXPERIMENTAL
Intervention: Coumadin (Boots)
Number of subjects: 12
Study 3057655 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (Lennon)
Number of subjects: 12
Study 29199002 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinner at 2100h (D21)
Number of subjects: 14
Study 29199002 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided dinner (DD)
Number of subjects: 14
Study 29530224 — intervention group
Group type: EXPERIMENTAL
Intervention: BPAC Inc. TIA/stroke electronic decision support (EDS) for GPs
Number of subjects: 291
Study 29530224 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 291
Study 25365753 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TDV)
Number of subjects: 20869
Study 25365753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20869
Study 23298135 — intervention group
Group type: EXPERIMENTAL
Intervention: 500mg resveratrol/day for 30 days
Number of subjects: 50
Study 23298135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 21842613 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drug (specific drug not mentioned)
Number of subjects: 0
Study 21842613 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose or augmentation agent
Number of subjects: 0
Study 21842613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18073468 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidetector-row CT angiography (CTA)
Number of subjects: 33
Study 18073468 — intervention group
Group type: COMPARATOR
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 33
Study 16467768 — intervention group
Group type: EXPERIMENTAL
Intervention: 200mg itraconazole twice daily during the first week of a 4 weeks cycle for 16 weeks
Number of subjects: 30
Study 16467768 — intervention group
Group type: COMPARATOR
Intervention: 250mg terbinafine twice daily during the first week of a 4 weeks cycle for 16 weeks
Number of subjects: 30
Study 12845417 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 40
Study 12845417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10811148 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg press power and habitual physical activity level
Number of subjects: 80
Study 10811148 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg power
Number of subjects: 80
Study 8785136 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltanolone
Number of subjects: 76
Study 8785136 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 76
Study 8785136 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 76
Study 8785136 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 76
Study 2050651 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 205
Study 2050651 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 205
Study 6687578 — intervention group
Group type: EXPERIMENTAL
Intervention: Agiolax (15 mg senna glucosides)
Number of subjects: 20
Study 6687578 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunelax comp. (25 mg senna glucoside A + B)
Number of subjects: 20
Study 30735064 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant Power Score
Number of subjects: 452
Study 30735064 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic mechanism of injury
Number of subjects: 452
Study 29504781 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 376